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The canonical Wnt pathway plays a central role
in stem cell maintenance, differentiation, and prolif-
eration in the intestinal epithelium. Constitutive,
aberrant activity of the TCF4/b-catenin transcrip-
tional complex is the primary transforming factor
in colorectal cancer. We identify a nuclear long
non-coding RNA, termed WiNTRLINC1, as a direct
target of TCF4/b-catenin in colorectal cancer cells.
WiNTRLINC1 positively regulates the expression of
its genomic neighbor ASCL2, a transcription factor
that controls intestinal stem cell fate. WiNTRLINC1
interacts with TCF4/b-catenin to mediate the juxta-
position of its promoter with the regulatory regions
of ASCL2. ASCL2, in turn, regulates WiNTRLINC1
transcriptionally, closing a feedforward regulatory
loop that controls stem cell-related gene expression.
This regulatory circuitry is highly amplified in colo-
rectal cancer and correlates with increased meta-
static potential and decreased patient survival. Our
results uncover the interplay between non-coding
RNA-mediated regulation and Wnt signaling and
point to the diagnostic and therapeutic potential of
WiNTRLINC1.INTRODUCTION
Stem cell maintenance and the proliferation/differentiation switch
in the adult, self-renewing intestinal epithelium are controlled by
the canonical Wnt pathway (Clevers and Nusse, 2012), which de-
termines developmental fates by regulating the transcriptional
output of TCF target genes. In the absence of Wnt ligands, a
destruction complex encompassing, among others, AXIN, APC,
and GSK3 tightly controls the cytosolic levels of b-catenin, the
key molecular effector of the pathway (Behrens et al., 1998).2588 Cell Reports 15, 2588–2596, June 21, 2016 ª 2016 The Author(
This is an open access article under the CC BY-NC-ND license (http://Upon physiological or mutationalWnt pathway activation, ubiqui-
tination of b-catenin is blocked; it translocates to the nucleus and
displaces corepressors from TCF4. This leads to activation of a
crypt stem/progenitor cell transcriptional program (Clevers and
Nusse, 2012; van de Wetering et al., 2002). Mutations in APC,
AXIN, or b-catenin lead to the constitutive nuclear localization of
the latter. The subsequent aberrant transcriptional activity of the
TCF4/b-catenin complex is the primary transforming factor in
colorectal cancer (Polakis, 2000).
Despite great recent inroads, the targets of Wnt-dependent
transcriptional regulation remain incompletely understood. The
binding sites of the relevant regulators in the genome are distrib-
uted mostly in distal gene locations, in regions of the genome
with few or no known nearby annotated genes (Bottomly et al.,
2010; Hatzis et al., 2008; Mokry et al., 2012; Schuijers et al.,
2014). This leaves open the possibility that other transcriptional
components of the pathway remain to be uncovered.
Long non-coding RNAs are such putativeWnt pathway targets
or regulators. Long intergenic non-coding RNAs (lincRNAs) iden-
tified in other systems frequently have been shown to act as
important regulators of transcriptional responses, among other
functions (Guttman et al., 2009; Mercer et al., 2009). For
instance, HOTAIR represses transcription in trans of the HOXD
locus. It does so by interacting with and linking repressive
histone modification complexes, such as PRC2 and LSD1/
CoREST/REST, thus modulating the chromatin structure of
affected loci, promoting cancer metastasis, and affecting
imprinting and developmental patterning (Gupta et al., 2010; Li
et al., 2013; Rinn et al., 2007; Tsai et al., 2010). The p53-induced
lincRNA-p21 activates p21 in cis to regulate the G1/S checkpoint
(Dimitrova et al., 2014). Its other putative functions include the
suppression of mRNA translation (Yoon et al., 2012), the modu-
lation of the Warburg effect (Yang et al., 2014), and gene repres-
sion in trans (Huarte et al., 2010).
Long non-coding RNAswith enhancer-like functions also have
been identified in human cells; they interact with components of
the Mediator co-activator complex to mediate loop formation
between non-coding RNA (ncRNA)-a loci and neighboring pro-
tein-coding genes and positively affect the expression of thes).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. WiNTRLINC1 Controls the Prolif-
eration and Survival of Cancer Cells
(A) Snapshots show ChIP-seq and RNA-seq reads
at the genomic region encompassing WiNTR-
LINC1 and ASCL2.
(B) The qPCR analysis of WiNTRLINC1 (and LGR5
as control), with and without overexpression of
shRNAs against b-catenin or of a dominant-nega-
tive form of TCF4, is shown.
(C) Colony formation assay with and without
knockdown of WiNTRLINC1. Cells with inducible
expression of scrambled shRNAs are shown as
control.
(D) FACS analysis of cell-cycle profiles of Ls174T
cellswith andwithout knockdownofWiNTRLINC1.
Analysis was performed 192 hr after the addition of
doxycycline.
(E) FACS analysis of apoptotic and necrotic pro-
files of Ls174T cells with and without knockdown
of WiNTRLINC1. Analysis was performed 192 hr
after the addition of doxycycline (*p value < 0.05
calculated with ANOVA). Data are mean ± SD of
three independent biological replicates.latter (Lai et al., 2013; Ørom et al., 2010; Trimarchi et al.,
2014). These and other recent examples highlight the impor-
tance of these RNA species in the regulation of the trans-
criptional and epigenetic landscapes in diverse tissues and
disease and developmental contexts (Bonasio and Shiekhattar,
2014).
RESULTS
To identify Wnt-regulated long non-coding RNAs, we took
advantage of previously generated colorectal carcinoma (CRC)
cell lines (derived from LS174T) engineered to inducibly overex-
press a small hairpin RNA (shRNA) against b-catenin or a domi-
nant-negative mutant of TCF4 (van de Wetering et al., 2002,
2003). Doxycycline induction leads, in both cases, to robust
abrogation of the TCF4/b-catenin-driven transcriptional program
in these cells. Chromatin immunoprecipitation (ChIP) followed byCell Rhigh-throughput sequencing (ChIP-seq)
with antibodies against RNA polymerase
II (Pol II), before and after Wnt pathway
abrogation, reveals sites of Wnt-depen-
dent transcription (Mokry et al., 2012).
This includes not only annotated long
non-coding RNAs but also regions with
no previously annotated genes or other
transcripts. Many of these regions over-
lap with or are reminiscent of similar sites
of transcription of lincRNAs identified
previously on the basis of chromatin state
marks (Guttman et al., 2009; Khalil et al.,
2009).
One such region was located in the vi-
cinity of the ASCL2 locus, which encodes
a transcription factor that controls intesti-
nal stemcell fate (vanderFlier et al., 2009):at a distance of 60 kb from ASCL2, the region is marked by tri-
methylation of histone H3 at lysine 4 and TCF4- (Mokry et al.,
2010) and b-catenin- (Schuijers et al., 2014) binding sites in the vi-
cinity of thePol II domain, and it transcribes aWnt-regulated tran-
script, as revealed by RNA sequencing (RNA-seq) transcriptional
profiling in cells inducibly overexpressing an shRNA against
b-catenin (Mokry et al., 2012) (Figure 1A, labeled WiNTRLINC1,
see below). We confirmed the TCF4/b-catenin dependency of
the transcript with qRT-PCR experiments in cells with b-catenin
knockdown and in cells inducibly overexpressing a dominant-
negative mutant of TCF4 (Figures 1B and S1A). Importantly, the
transcript was expressed and regulated by b-catenin in other
CRC cell lines, such as CaCo2 and DLD1 (Figure S1A).
Rapid amplification of cDNA ends (RACE) allowed the cloning
of a full-length transcript of 4,117 bp, which was produced from
a single exon. Northern blot analysis of polyA-enriched RNA
confirmed thepresenceof a long, polyadenylated,Wnt-regulatedeports 15, 2588–2596, June 21, 2016 2589
BE
C
C
O
N
TR
O
L
W
iN
TR
LI
N
C
1 
K
D
RNA seq
WiNTRLINC1 ASCL2
839
839
0
0
WiNTRLINC1 
KD
1718
398
P=0.005
1211
ASCL2       
KD
WiNTRLINC1   
KD
ASCL2    
KD
4 -4
0.0 
-0.1 
-0.2 
-0.3 
15
10
5
0
0 5000 10000 15000
FO
LD
C
H
AN
G
E
AS
C
L2
 R
EG
U
LA
TO
R
Y 
SC
O
R
E
ASCL2 KD
WiNTRLINC1 KD
ASCL2 KD
GENE RANK
D
A
2-1
-lo
g1
0P
VA
LU
E
FOLD CHANGE (log2)
-3 -2 0 1 3
ASCL2
Stem cell marker
Apoptosis
Differentiation
Cell proliferation
Oncogene
16 -
12-
8 -
4 -
0 -
20 -
24 -
ETS2
CDK6
E2F1
RAC1
USP22
MT2A
SMOC2
CASP7
TNFRSF1B FOSL1
FOXQ1
CACNA1H
CALB2
CLSPN
MUC5AC
ANXA3
TP53
TP73
FOXM1
PRSS3 VILL
TNFRSF21
KRT4
EMP1
0
5
10
15
20
N
O
R
M
AL
IS
ED
 E
XP
R
ES
SI
O
N
Ls
17
4
C
AC
O
-2
D
LD
1
SW
48
0
H
C
T1
16
H
T2
9
ASCL2WiNTRLINC1
qPCR
Figure 2. WiNTRLINC1 Positively Regulates
ASCL2 Expression
(A) Volcano plot showing the differentially ex-
pressed genes upon WiNTRLINC1 knockdown.
Green and red dots mark significantly down- and
upregulated genes, respectively (fold change 1.53,
p value < 0.05). Blue dots mark selected examples
of deregulated genes that are color coded accord-
ing to their functional annotation.
(B) Snapshot of RNA-seq signal over the
WiNTRLINC1 and ASCL2 loci, in control cells and
upon WiNTRLINC1 knockdown. RNA harvesting
was performed 72 hr after doxycycline addition.
(C) WiNTRLINC1 expression correlates with
ASCL2 in a panel of colon cancer cell lines, with
Ls174T cells showing the highest expression of
both transcripts and HCT116 and HT29 showing
no expression.
(D) Venn diagram and heatmap of the common
differentially expressed genes after WiNTRLINC1
and ASCL2 knockdown are shown.
(E) Correlation between the deregulation of gene
expression in the WiNTRLINC1 and ASCL2 knock-
down datasets (upper panel) and the regulatory
potential of ASCL2 (lower panel). Increased regu-
latory potential by ASCL2 of a gene correlates
with increasingly deregulated expression upon
WiNTRLINC1 and ASCL2 knockdown.RNAspecies inCRCcells (FigureS1B). PhyloCSF (Lin et al., 2011)
(Figure S1C) and InterProScan5 (Figure S1D) analyses revealed
the transcript to have very low protein-coding potential, and
in vitro transcription-translation assays produced no protein
from the transcript (Figure S1E). Fractionation of cell extracts fol-
lowed by qPCR analyses (Chalkiadaki and Talianidis, 2005)
showed it tobepredominantlychromatinassociated (FigureS1F).
We confirmed that the putative proximal promoter region of the
transcript (the region surrounding the transcription start site
[TSS], as defined by 50 RACE) is bound by TCF4 and b-catenin
in a ChIP-qPCR assay (Figure S1G) and that it can drive Wnt-
dependent transcription of a luciferase reporter (Figure S1H).
Based on the low protein-coding potential of the transcript, its
predominant localization in chromatin, and its direct regulation
by the TCF4/b-catenin complex, we have named it WNT-regu-
lated lincRNA 1 (WiNTRLINC1).2590 Cell Reports 15, 2588–2596, June 21, 2016Conditional shRNA-mediated knock-
down of WiNTRLINC1 in LS174T cells
reduced WiNTRLINC1 transcript levels
to 30% of control cells (Figure S2A)
and dramatically affected cell growth, as
demonstrated by colony formation assays
(Figure 1C). WiNTRLINC1 knockdown
caused a partial G2 arrest (Figure 1D)
and a pronounced increase in apoptotic
and necrotic cells (Figure 1E), as revealed
by propidium iodide or Annexin V/propi-
dium iodide staining, respectively, point-
ing to a role of WiNTRLINC1 in correct
cell-cycle progression and protection of
cells from apoptosis. Differential expres-sion analysis after RNA-seq revealed 1,609 genes deregulated
after WiNTRLINC1 knockdown, with 890 genes downregulated
and 719 genes upregulated >1.53 (p < 0.05) (Figure 2A;
Table S1). The list of deregulated genes was enriched in genes
involved in differentiation, cell proliferation, apoptosis, as well as
stemcellmarkers, oncogenes, and tumor suppressors (Figure 2A;
see below), consistent with the phenotype observed after
WiNTRLINC1 abrogation.
Prominent among the most significantly deregulated genes
was ASCL2, the closest WiNTRLINC1 protein-coding neighbor,
a Wnt-responsive gene whose product is required for stem cell
maintenance in the intestine (Schuijers et al., 2015; van der Flier
et al., 2009). Both shRNA- and small interfering RNA (siRNA)-
mediated knockdown of WiNTRLINC1 led to the decrease of
ASCL2 levels (Figures 2B and S2A). ASCL2 expression tightly
followedWiNTRLINC1 levels in a panel of colon cancer cell lines.
Ls174T cells displayed maximum levels for both transcripts (Fig-
ure 2C). Based on this and the proximity of the two loci, we
reasoned that WiNTRLINC1may exert its functions on cell prolif-
eration and viability predominantly through regulation of ASCL2
expression.
To investigate this hypothesis, we compared differentially regu-
lated genes in WiNTRLINC1- and ASCL2-knockdown Ls174T
cells. RNA-seq-baseddifferential expression analysis after induc-
ible shRNA-mediated ASCL2 knockdown (van der Flier et al.,
2009) revealed 2,116 genes to be deregulated, 1,144 up-
and972downregulated>1.53 (p < 0.05) (TableS2). The two da-
tasets demonstrated ahighly significant overlapof398common
targets (p = 0.0051) (Figure 2D; Table S3). Interestingly, the com-
mon targets—mostly deregulated in the same direction—belong
to relevant enriched gene ontology categories, such as the regu-
lation of apoptosis, cell proliferation, differentiation, stemness,
and oncogenesis (Table S4). We further took advantage of the
ASCL2 genome-wide binding pattern in these cells (more than
8,000 genomic locations were bound by ASCL2 in Ls174T)
(Schuijers et al., 2015) to calculate a regulatory score for ASCL2,
which takes into account ASCL2 peak occurrence and binding
pattern and reflects the probability of direct regulation of a gene
by ASCL2. Interestingly, the regulatory score highly correlated
with the extent of deregulation of gene expression, both after
ASCL2 as well as after WiNTRLINC1 knockdown, as the genes
mostseverely transcriptionally affectedwere theonesmostprom-
inently bound by ASCL2 (exhibiting the highest regulatory score)
(Figure 2E). In addition, we complemented WiNTRLINC1-knock-
down cells with exogenous ASCL2 (by generating a cell line
that, upon doxycycline induction, simultaneously overexpresses
FLAG-ASCL2 and shRNA against WiNTRLINC1) (Figure S2A).
ASCL2binding to target loci (FigureS2B), transcriptionof its target
genes (Figure S2C), and cellular viability (Figure S2D) were
restored in these cells, pointing to ASCL2 as the major target of
WiNTRLINC1 function. Importantly, themolecular andphenotypic
effects ofWiNTRLINC1extendbeyond theLs174Tbackground to
other colon cancer cell line models, as siRNA-mediated knock-
down of WiNTRLINC1 in CaCo-2 and SW480 decreased tran-
scription of ASCL2, affected the expression of common target
genes (Figures S2E andS2F), anddecreasedcell survival (Figures
S2G and S2H). These results suggest that WiNTRLINC1 exerts
a significant part of its functions through controlling ASCL2
expression.
We reasoned that themechanism throughwhichWiNTRLINC1
exerts this regulatory function may involve the formation of a to-
pological loop between the two loci. Chromosome conformation
capture (3C) experiments demonstrated that the TSS region of
WiNTRLINC1 interacts with the region immediately downstream
of the ASCL2 locus (ASCL2 enhancer, a region characterized by
the absence of H3K4 trimethylation and the presence of Medi-
ator and H3K4 monomethylation and H3K27 acetylation, Fig-
ure S3A), in a WiNTRLINC1-dependent manner: knockdown of
the latter results in disruption of this loop (Figure 3A). The poten-
tial involvement of the ASCL2 promoter in this loop, which would
help explain its activation, could not be investigated because of a
lack of suitable restriction sites. We employed chromatin isola-
tion with RNA purification (ChIRP) (Chu et al., 2011) to examine
the physical presence of the WiNTRLINC1 transcript on the re-gions determined by 3C to be topologically juxtaposed. ChIRP
revealed the transcript to be localized to the WiNTRLINC1-tran-
scribed region, as expected. This localization was abolished by
WiNTRLINC1 downregulation after b-catenin knockdown (Fig-
ure 3B). Importantly, WiNTRLINC1 RNA also was recruited to
the WiNTRLINC1 promoter and the ASCL2 enhancer regions
(but not to the ASCL2 promoter region, data not shown) in a
similar b-catenin-dependent manner (Figure 3B). Both these
WiNTRLINC1-occupied, interacting genomic regions were
bound by TCF4 and b-catenin (see Figure 1A and below).
We next explored the possibility that TCF4 and b-catenin
might form a complex with WiNTRLINC1 to mediate loop forma-
tion. RNA immunoprecipitation (RIP) assays confirmed a specific
interaction between WiNTRLINC1 and TCF4 and b-catenin (Fig-
ure 3C). WiNTRLINC1 knockdown led to dramatically decreased
recruitment of TCF4, b-catenin (Figures S3B and S3C), and Pol II
(Figure S3D), as well as decreased H3K4 monomethylation,
H3K27 acetylation, and Mediator recruitment on the relevant
genomic regions of WiNTRLINC1 and ASCL2 (Figures S3E–
S3G). These data demonstrate that WiNTRLINC1 orchestrates
factor recruitment, physical juxtaposition, and activity of the reg-
ulatory regions that maintain ASCL2 expression.
The eventuality of a reciprocal relationship between
WiNTRLINC1 and ASCL2 became evident upon visual inspec-
tion of the ASCL2-binding profile around the relevant loci: it
featured a prominent binding site on the promoter region of
WiNTRLINC1 (Figures 3D and S2B). The RNA-seq signal over
WiNTRLINC1 was concomitantly diminished upon ASCL2
knockdown (Figures 3D and S2A). A regulatory scheme that
emerges from the above data involves the TCF4/b-catenin tran-
scription complex binding to and activating the WiNTRLINC1
promoter region; it then interacts with the transcribed RNA to
stabilize a loop juxtaposing the WiNTRLINC1 promoter and the
30 ASCL2 regulatory regions, driving high-level ASCL2 expres-
sion. This topological loop requires WiNTRLINC1 for its stability.
The regulatory loop is enhanced and completed by reciprocal
ASCL2 binding to theWiNTRLINC1 promoter to drive transcrip-
tion of the lincRNA (Figure S3I).
Additional support for this order of events was provided by ex-
periments in the cell line where WiNTRLINC1 knockdown was
complemented with exogenous ASCL2: overexpression of the
latter restored ASCL2 binding to theWiNTRLINC1 promoter (Fig-
ure S2B) and WiNTRLINC1 transcription (as measured by Pol II
occupancy, Figure S3D), but not, as expected, WiNTRLINC1
transcript levels (Figure S2A). This restored transcription of
WiNTRLINC1 was not sufficient to reestablish binding of TCF4
or b-catenin to the WiNTRLINC1 promoter or ASCL2 enhancer
(Figures S3B and S3C) or the previous histone modification sta-
tus of the latter (Figures S3E and S3F); neither did it reestablish
loop formation between the WiNTRLINC1 and ASCL2 loci (Fig-
ure S3H) or endogenous ASCL2 transcription (Figure S3D) or
RNA levels (Figure S2A). These results demonstrate that the
WiNTRLINC1 RNA product is essential both for loop formation
and for expression of ASCL2: the act of transcription of WiNTR-
LINC1 is not sufficient for either event. They also show that hu-
man ASCL2 cannot activate its own transcription without
WiNTRLINC1, lending additional support to the regulatory
scheme outlined in Figure S3I.Cell Reports 15, 2588–2596, June 21, 2016 2591
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Figure 3. Mechanism of WiNTRLINC1-Mediated Control of ASCL2 Expression
(A) Normalized interaction frequencies between the WiNTRLINC1 and the ASCL2 loci, as revealed by 3C-qPCR, using an anchor primer (red arrowhead) and test
primers (black arrowheads). ChIP-seq signals for TCF4, b-catenin, and Pol II over the region are highlighted at the top.
(B) ChIRP-qPCR analysis for WiNTRLINC1 over the WiNTRLINC1 and the ASCL2 loci using the indicated primer pairs (pairs of green arrowheads) is shown.
(C) RIP of b-catenin, TCF4, or IgG control coupled to qPCR with primers for the indicated RNAs is shown.
(D) Snapshots of ChIP-seq reads for ASCL2 and RNA-seq reads after ASCL2 knockdown, at the genomic region encompassing WiNTRLINC1 and ASCL2
(*p value < 0.05, **p value < 0.01, and ***p value < 0.001, calculated with ANOVA). Data are mean ± SD of three independent biological replicates. All experiments
were performed 72 hr after doxycycline addition.
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AB
C
D
Figure 4. The WiNTRLINC1-ASCL2 Regula-
tory Loop Is Amplified in Colorectal Cancer
(A) Summarized expression of WiNTRLINC1 (left
panel) and ASCL2 (right panel) in a set of 434 tumor
and 40 normal samples from the colon cancer
dataset of TCGA Network. Inset shows expression
of each gene as boxplots (*p value < 0.05 calcu-
lated with ANOVA).
(B) Correlation analysis of WiNTRLINC1 and
ASCL2 expression in the normal and tumor sam-
ples of (A) is shown.
(C) Kaplan-Meier analysis and log-rank p value for
overall survival, comparing colon cancer patients
with high and low WiNTRLINC1 expression, are
shown.
(D) Principal-component analysis for normal
versus tumor sample discrimination based on
gene expression in the TCGA colon cancer patient
panel. Left panel demonstrates sample loadings
for component 1 (25% of total variability) effec-
tively separating normal samples (positive load-
ings shown with blue marks) from tumor samples
(negative loadings shown with read marks). Right
panel illustrates gene loadings for the same
component. WiNTRLINC1 is ranked at position
237 and ASCL2 at position 158 among 11,537
genes. Other known oncogenes and differentiation
genes also are shown.The genomic region proximal to ASCL2, at chromosome arm
11p.15.5, has recently been found to be focally amplified in
7% of the colorectal tumors analyzed by The Cancer Genome
Atlas (TCGA) Network (2012). The amplified region does not
include ASCL2; we observed, however, that, in addition to genes
such as IGF2, INS, TH, and miR-483, it frequently included the
WiNTRLINC1 locus; this served as an impetus for us to reanalyze
the TCGA RNA-seq data to investigate WiNTRLINC1 expression
levels in colorectal cancer. WiNTRLINC1 was robustly overex-
pressed in the tumor samples, coupled with concordant
overexpression of ASCL2 (Figures 4A and 4B). We verified this
overexpression by qPCR in a panel of normal and colorectal can-
cer patient samples; WiNTRLINC1 and ASCL2 expression were
significantly correlated (FigureS4A), demonstrating the amplifica-
tion of theWiNTRLINC1-ASCL2 regulatory loop in colorectal can-
cer. Hierarchical clustering of expressed genes in normal and
tumor samplesof theTCGApanel further illustrated this regulatoryCell Rrelationship, as WiNTRLINC1 and ASCL2
expression were tightly linked across 434
tumor and 40 normal samples; pairwise
correlation analysis between WiNTR-
LINC1 and each of the 11,537 expressed
genes in the TCGA panel, using different
metrics (see Experimental Procedures),
consistently ranked the WiNTRLINC1-
ASCL2 pair in the top position in the order
of correlation strength (R2 = 0.60).
Stratification of the TCGA tumors into
higher- and lower-expressing cohorts
(Figure S4B) coupled to Kaplan-Meier
analysis revealed that high-level WiNTR-
LINC1 expression correlates significantly with lower overall prob-
ability of survival (Figure 4C), lower disease-free survival (Fig-
ure S4C), worse disease progression (Figure S4D), higher
probability for lymph node invasion (Figure S4E) and greater met-
astatic potential (FigureS4F).HighASCL2expression significantly
correlates only with lower disease-free survival (Figure S4G) and
not with the other characteristics tested (Figures S4H–S4K); this
isperhapsnot surprising,given thealreadysignificant overexpres-
sion of ASCL2 (and WiNTRLINC1) in the ‘‘low’’ tumor category
compared to normal samples (Figures S4L–S4O). The increased
mRNA levels of ASCL2 in the low group may already be sufficient
to lead to full phenotypic changes in tumor cells. In addition, the
amounts of ASCL2 mRNA in the low group may already produce
near-saturating levels of protein that are not further increased by
an additional increase in Ascl2 mRNA in the high group.
Principal-component analysis of gene expression values
across the TCGA patient panels allowed for the separation ofeports 15, 2588–2596, June 21, 2016 2593
normal from tumor samples (Figure 4D). WiNTRLINC1 and
ASCL2 exhibited high discriminatory power for tumor-normal
classification; theywere among the highest ranking genes (at po-
sitions 237 and 158, respectively) among 11,537 expressed
genes across the TCGA samples. This reinforces our findings,
highlighting the WiNTRLINC1-ASCL2 regulatory relationship
and its amplification in colorectal cancer.
DISCUSSION
ASCL2 has been shown to function as a master regulator of the
intestinal stem cell (van der Flier et al., 2009). It controls the
expression of genes fundamental to the stem cell state, by syn-
ergizing with TCF4/b-catenin on target gene regulatory regions
(Schuijers et al., 2015). In the mouse, it also has been reported
to be regulated by an auto-activating loop, which maintains
Ascl2 expression levels in a hysteretic manner, enabling it
to maintain its expression even upon fluctuation of the initial
activating Wnt signal (Schuijers et al., 2015). The most parsimo-
nious explanation of the results presented here is that human
ASCL2 is not directly regulated by Wnt: the direct Wnt target is
WiNTRLINC1, a neighboring cis-acting lincRNA. Upon activation
by TCF4/b-catenin, WiNTRLINC1 interacts with TCF4/b-catenin
and mediates their recruitment/stabilization, through the forma-
tion of a topological loop, to the 30 regulatory regions of ASCL2.
The recruitment of ASCL2 to theWiNTRLINC1 promoter, in turn,
enhances its expression and closes a feedforward regulatory
loop that is compatible with driving hysteretic expression of
human ASCL2.
Our results also provide support for the role of WiNTRLINC1 in
human colorectal cancer. ASCL2 is upregulated in human intes-
tinal neoplasia (Jubb et al., 2006), and an ASCL2-related stem
cell signature is expressed in colorectal cancer liver metastases
with the 11p15.5 gain, which involves theWiNTRLINC1-contain-
ing genomic region (Stange et al., 2010). While a potential
contribution of cytoplasmically localized WiNTRLINC1, possibly
independent of ASCL2, could not be determined at this point, the
feedforward regulatory loop we have uncovered here is robustly
amplified in human colorectal cancer. The correlation of
WiNTRLINC1 expression with patient survival and other clinical
characteristics warrants the exploration of its diagnostic and
therapeutic potential in colorectal cancer.
EXPERIMENTAL PROCEDURES
Cell Lines
Ls174T, CaCo2, DLD1, and SW480 cells were used in this study. Ls174T cells
that inducibly overexpress a dominant-negative form of TCF4 or an shRNA
against b-catenin or ASCL2 after treatment with doxycycline (1 mg/ml) have
been described previously (van de Wetering et al., 2002, 2003; van der Flier
et al., 2009). To generate Ls174T cells inducibly overexpressing an shRNA
against WiNTRLINC1, oligonucleotides 50-GATCCCCAGGGAGGCTGAAGA
GCAATTCAAGAGATTGCTCTTCAGCCTCCCTGTTTTTGGAAA-3 and 50-AGC
TTTTCCAAAAACAGGGAGGCTGAAGAGCA ATCTCTTGAATTGCTCTTCAGC
CTCCCTGGG-30 were used in conjunction with the pTER system, as
described (van de Wetering et al., 2003). The conditional ASCL2 overexpres-
sion (CASOX) cells, conditionally overexpressing ASCL2 after treatment with
doxycycline and in parallel to overexpression of shRNA against WiNTRLINC1,
were generated after transfection of a stable Ls174T clone overexpressing
shRNAs against WiNTRLINC1, as described above, with a modified PCDNA32594 Cell Reports 15, 2588–2596, June 21, 2016vector overexpressing a FLAG-tagged version of ASCL2, under the control of a
CMV promoter fused to Tet operator sequences.
RNA Isolation and Deep Sequencing
Total RNA was isolated with TRI reagent (Molecular Research Center) and
10 mg was treated with DNaseI (Promega) according to the manufacturer’s
protocols. DnaseI-treated RNA was extracted with phenol/chloroform, chloro-
form, and ethanol precipitation. RNA-seq was performed as described (Niko-
laou et al., 2015).
RIP
Ls174T cells (53 106) were plated in 1503 20-mm tissue culture dishes (Sar-
stedt) and were grown in DMEM for 72 hr. Cells were crosslinked with 1%
formaldehyde for 30 min at room temperature and quenched with glycine.
Chromatin was sonicated for 10min using the Covaris S series SonoLAB single
instrument with the following settings: duty cycle 20%, intensity 10, and cy-
cles/burst 1,000. RIP was performed as described (Rinn et al., 2007) with
20 mg antibody against b-catenin (sc7199, Santa Cruz Biotechnology) and
TCF4 (sc8631, Santa Cruz Biotechnology). RNA was eluted after incubation
at 37C for 20 min, de-crosslinked with 200 mM NaCl at 65C for 5 hr, and
extracted with TRI reagent (Molecular Research Center) as described above.
Extracted RNA was DNaseI treated, and cDNA synthesis was performed
with SuperScript II (Invitrogen) according to the manufacturer’s recommenda-
tions. All primers are shown in Table S5. Data are from three independent
biological replicates. ANOVA was performed in SigmaStat/Plot.
3C
Ls174T cells (5 3 106), conditionally overexpressing shRNAs against ASCL2
and WiNTRLINC1 with and without parallel ASCL2 overexpression, were
plated in 150 3 20-mm tissue culture dishes (Sarstedt), and they were grown
in DMEM for 72 hr with and without doxycycline. Cells were crosslinked with
1% formaldehyde for 10 min at room temperature, and 3C was performed
as described (Naumova et al., 2012), using the BglII restriction endonuclease
(Minotech). Digested chromatin was tested with electrophoresis in 1%
agarose gel, and digestion efficiency was tested with qPCR using primers
flanking the BglII restriction sites. Digested chromatin was ligated as
described (Naumova et al., 2012) and tested again with qPCR with the same
primers as for digestion efficiency. After ligation, the chromatin was de-cross-
linked with 200 mM NaCl at 65C, treated with RNase A, and extracted with
phenol/chloroform, chloroform, and ethanol precipitation. 3C digestion and
ligation conditions were optimized with a BAC clone containing both the
WiNTRLINC1 and the ASCL2 loci (BACPAC resources RP11-542J6). 3C-
qPCR also was performed with the BAC DNA, which was used as control for
the digestion and ligation efficiency tests, as well as for quantifying the
genomic 3C qPCR results. 3C amplicons were validated with BglII digests
and Sanger sequencing. All primers are shown in Table S5. Data are from three
independent biological replicates. ANOVA was performed in SigmaStat/Plot.
ChIRP
ChIRP was performed as described (Chu et al., 2011), with the following mod-
ifications: Ls174T cells, control or overexpressing shRNAs against b-catenin,
were grown in DMEM in the absence or presence, respectively, of doxycycline
for 72 hr, after which they were washed with PBS and crosslinked with 1%
glutaraldehyde/PBS for 20min at room temperature. Chromatin was sonicated
for 30 min using the Covaris S series SonoLAB single instrument with the
following settings: duty cycle 20%, intensity 10, and cycles/burst 1,000. Hy-
bridization was performed overnight at 37C, and oligo capturing was per-
formed for 30 min at 37C with 150 ml streptavidin-coated beads per sample
(Dynabeads MyOne Streptavidin C1, Invitrogen). Odd and even pools of bio-
tynilated oligonucleotides complementary to the mRNA sequence of WiNTR-
LINC1 were used to capture WiNTRLINC1-bound chromatin. A symmetrical
set of probes against lacZ RNA also was generated as the mock control. All
probe sequences are shown in Table S5. DNA was eluted; de-crosslinked
with 15 ml proteinase K (10 mg/ml) for 45 min at 50C; extracted with phenol/
chroloform, chloroform, and ethanol precipitation; and subsequently diluted
with ddH2O to 240 ml for qPCR. Data are from three independent biological
replicates. ANOVA was performed in SigmaStat/Plot.
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